Optimizing aerosol delivery by pressurized metered-dose inhalers

Respiratory Care

Volumn 50, Issue 9, 2005, Pages 1191-1197

  Rubin, Bruce K ^a   Fink, James B ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b Aerogen   (United States)

Author keywords

Aerosol; Drug delivery; MDI; Metered dose inhaler

Indexed keywords

ADRENALIN; BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CHLOROFLUOROCARBON; CORTICOSTEROID DERIVATIVE; FLUORINATED HYDROCARBON; FLUTICASONE; FORMOTEROL; IPRATROPIUM BROMIDE; ISOPRENALINE; PIRBUTEROL; PROPELLANT; SALBUTAMOL; SALMETEROL; STEROID;

AEROSOL; ASTHMA; BREATHING PATTERN; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFERENCE PAPER; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FACE MASK; FOOD AND DRUG ADMINISTRATION; HUMAN; METERED DOSE INHALER; PATIENT COMPLIANCE; PATIENT EDUCATION; SURFACE CHARGE; TOXICITY; BREATHING MECHANICS; DRUG EFFECT; EQUIPMENT DESIGN; INHALATION SPACER; INHALATIONAL DRUG ADMINISTRATION; LUNG; MASK; METHODOLOGY; REVIEW; TEMPERATURE;

ADMINISTRATION, INHALATION; AEROSOL PROPELLANTS; CHLOROFLUOROCARBONS; DOSE-RESPONSE RELATIONSHIP, DRUG; EQUIPMENT DESIGN; HUMANS; HYDROCARBONS, FLUORINATED; INHALATION SPACERS; LUNG; MASKS; METERED DOSE INHALERS; PATIENT COMPLIANCE; PATIENT EDUCATION; RESPIRATORY MECHANICS; TEMPERATURE;

EID: 33644627141     PISSN: 00201324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (61)

1. Freedman T. Medihaler therapy for bronchial asthma: a new type of aerosol therapy. Postgrad Med 1956;20:667-673.
2. Dolovich MB, Ahrens RC, Hess DR, Anderson P, Dhand R, Rau JL, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines. Chest 2005;127(1):335-371.
3. Robertson CF, Norden MA, Fitzgerald DA, Connor FL, Van Asperen PP, Cooper PJ, et al. Treatment of acute asthma: salbutamol via jet nebuliser vs spacer and metered dose inhaler. J Paediatr Child Health 1998;34(2):142-146.
4. Leversha AM, Campanella SG, Aickin RP, Asher MI. Costs and effectiveness of spacer versus nebulizer in young children with moderate and severe acute asthma. J Pediatr 2000;136(4):497-502.
5. Dewar AL, Stewart A, Cogswell JJ, Connett GJ. A randomised controlled trial to assess the relative benefits of large volume spacers and nebulisers to treat acute asthma in hospital. Arch Dis Child 1999; 80(5):421-423.
6. Gazarian M, Henry RL, Wales SR, Micallef BE, Rood EM, O'Meara MW, Numa AH. Evaluating the effectiveness of evidence-based guidelines for the use of spacer devices in children with acute asthma. Med J Aust 2001;174(8):394-397.
7. Cates CJ, Rowe BH, Bara A. Holding chambers versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev 2000(2):(CD000052).
8. Thiel CG. From Susie's question to CFC free: an inventor's perspective on forty years of MDI development and regulation. In: Dalby RN, Byron PR, Farr SJ, editors. Respiratory drug delivery V Vol 1. Buffalo Grove: Interpharm Press; 1996:115-123.
9. van der Palen J, Klein JJ, van Herwaarden CL, Zielhaus GA, Seydel ER. Multiple inhalers confuse asthma patients. Eur Respir J 1999; 14(5):1034-1037.
10. Blake KV, Harman E, Hendeles L. Evaluation of a generic albuterol metered-dose inhaler: importance of priming the MDI. Ann Allergy 1992;68(2):169-174.
11. Rubin BK, Fink JB. The delivery of inhaled medication to the young child. Pediatr Clin North Am 2003;50(3):717-731.
12. Kamps AW, Brand PL, Roorda RJ. Determinants of correct inhalation technique in children attending a hospital-based asthma clinic. Acta Paediatr 2002;91(2):159-163.
13. Rubin BK. What does it mean when a patient says, "my asthma medication isn't working"? Chest 2004;126(3):972-981.
14. Rubin BK, Durotoye L. How do patients determine that their metered-dose inhaler is empty? Chest 2004;126(4):1134-1137.
15. Wilson AF, Mukai DS, Ahdout JJ. Effect of canister temperature on performance of metered-dose inhalers. Am Rev Respir Dis 1991; 143(5 Pt 1):1034-1037.
16. Everard ML, Devadason SG, Summers QA, Le Souef PN. Factors affecting total and "respirable" dose delivered by a salbutamol metered dose inhaler. Thorax 1995;50(7):746-749.
17. The Montreal Protocol on Substances that Deplete the Ozone Layer, as adjusted and/or amended in London 1990, Copenhagen 1992, Vienna 1995, Montreal 1997, and Beijing 1999. http://www.unep. org/ozone/montreal-protocol/montreal- protocol2000.shtml. Accessed June 23, 2005.
18. Leach C. Enhanced drug delivery through reformulating MDIs with HFA propellants-drug deposition and its effect on preclinical and clinical programs. In: Dalby RN, Byron PR, Farr SJ, editors. Respiratory drug delivery V Vol 1. Buffalo Grove: Interpharm Press; 1996:133-143.
19. Berry J, Heimbecher S, Hart JL, Sequeira J. Influence of the metering chamber volume and actuator design on the aerodynamic particle size of a metered dose inhaler. Drug Dev Ind Pharm 2003;29(8): 865-876.
20. Janssens HM, De Jongste JC, Hop WC, Tiddens HA. Extra-fine particles improve lung delivery of inhaled steroids in infants: a study in an upper airway model. Chest 2003;123(6):2083-2088.
21. Smith KJ, Chan HK, Brown KF. Influence of flow rate on aerosol particle size distributions from pressurized and breath actuated inhalers. J Aerosol Med 1998;11(4):231-245.
22. Ruggins NR, Milner AD, Swarbrick A. An assessment of a new breath actuated inhaler device in acutely wheezy children. Arch Dis Child 1993;68(4):477-480.
23. Everard ML. Guidelines for devices and choices. J Aerosol Med 2001;14 Suppl 1:S59-S64.
24. Wilkes W, Fink J, Dhand R. Selecting an accessory device with a metered-dose inhaler: variable influence of accessory devices on fine particle dose, throat deposition, and drug delivery with asynchronous actuation from a metered-dose inhaler. J Aerosol Med 2001;14(3): 351-360.
25. Zar HJ, Asmus MJ, Weinberg EG. A 500-mL plastic bottle: an effective spacer for children with asthma. Pediatr Allergy Immunol 2002;13(3):217-222.
26. Rubin BK, Newhouse MH, Barnes PJ. Conquering childhood asthma. Hamilton, Ontario, Canada: BC Decker; 1998.
27. Barry PW, O'Callaghan C. Multiple actuations of salbutamol MDI into a spacer device reduce the amount of drug recovered in the respirable range. Eur Respir J 1994;7(9):1707-1709.
28. Clark DJ, Lipworth BJ. Effect of multiple actuations, delayed inhalation and antistatic treatment on the lung bioavailability of salbutamol via a spacer device. Thorax 1996;51(10):981-984.
29. Barry PW, O'Callaghan C. The effect of delay, multiple actuations and spacer static charge on the in vitro delivery of budesonide from the Nebuhaler. Br J Clin Pharmacol 1995;40(1):76-78.
30. O'Callaghan C, Lynch J, Cant M, Robertson C. Improvement in sodium cromoglycate delivery from a spacer device by use of an antistatic lining, immediate inhalation, and avoiding multiple actuations of drug. Thorax 1993;48(6):603-606.
31. Wildhaber JH, Devadason SG, Eber E, Hayden MJ, Everard ML, Summers QA, LeSouef PN. Effect of electrostatic charge, flow, delay and multiple actuations on the in vitro delivery of salbutamol from different small volume spacers for infants. Thorax 1996;51(10): 985-988.
32. Anhøj J, Bisgaard H, Lipworth BJ. Effect of electrostatic charge in plastic spacers on the lung delivery of HFA-salbutamol in children. Br J Clin Pharmacol 1999;47(3):333-336.
33. Wildhaber JH, Janssens HM, Pierart F, Dore ND, Devadason SG, LeSouef PN. High-percentage lung delivery in children from detergent-treated spacers. Pediatr Pulmonol 2000;29(5):389-393.
34. Dubus JC, Guillot C, Badier M. Electrostatic charge on spacer devices and salbutamol response in young children. Int J Pharm 2003; 261(1-2):159-164.
35. O'Callaghan C. In vitro performance of plastic spacer devices. J Aerosol Med 1997;10 Suppl 1:S31-S35.
36. Pierart F, Wildhaber JH, Vrancken I, Devadason SG, Le Souef PN. Washing plastic spacers in household detergent reduces electrostatic charge and greatly improves delivery. Eur Respir J 1999;13(3):673-678.
37. Dompeling E, Oudesluys-Murphy AM, Janssens III, Hop W, Brinkman JG, Sukhai RN, de Jongste JC. Randomised controlled study of clinical efficacy of spacer therapy in asthma with regard to electrostatic charge. Arch Dis Child 2001;84(2):178-182.
38. Murakami G, Igarashi T, Adachi Y, Matsuno M, Adachi Y, Sawai M, et al. Measurement of bronchial hyperreactivity in infants and preschool children using a new method. Ann Allergy 1990;64(4): 383-387.
39. Iles R, Lister P, Edmunds AT. Crying significantly reduces absorption of aerosolized drug in infants. Arch Dis Child 1999;81(2):163-165.
40. Amirav I, Newhouse MT. Aerosol therapy with valved holding chambers in young children: importance of the face mask seal. Pediatrics 2001;108(2):389-394.
41. Onhøj J, Thorsson L, Bisgaard H. Lung deposition of inhaled drugs increases with age. Am J Respir Crit Care Med 2000;162(5):1819-1822.
42. Chua HL, Collis GG, Newbury AM, Chan K, Bower GD, Sly PD, Le Souef PN. The influence of age on aerosol deposition in children with cystic fibrosis. Eur Respir J 1994;7(12):2185-2191.
43. Le Souef P. The meaning of lung dose. Allergy 1999;54 Suppl 49:93-96.
44. Agertoft L, Andersen A, Weibull E, Pedersen S. Systemic availability and pharmacokinetics of nebulized budesonide in preschool children. Arch Dis Child 1999;80(3):241-247.
45. Mitchell JP, Nagel MW. In vitro performance testing of three small volume-holding chambers under conditions that correspond with use by infants and small children. J Aerosol Med 1997;10(4):341-349.
46. Everard ML, Clark AR, Milner AD. Drug delivery from holding chambers with attached facemask. Arch Dis Child 1992;67(5):580-585.
47. Williams RO 3rd, Barron MK. Influence of temperature on the emitted dose of an oral metered dose inhaler. Drug Dev Ind Pharm 1998;24(11):1043-1048.
48. DeHaan WH, Finlay WH. In vitro monodisperse aerosol deposition in a mouth and throat with six different inhalation devices. J Aerosol Med 2001;14(3):361-367.
49. Terzano C. Pressurized metered dose inhalers and add-on devices. Pulmonol Pharmacol Therap 2001;14(5):351-366.
50. Smyth HD, Beck VP, Williams D, Hickey AJ. The influence of formulation and spacer device on the in vitro performance of solution chlorofluorocarbon- free propellant-driven metered dose inhalers. AAPS PharmSciTech 2004;5(1):E7.
51. Slader CA, Reddel HK, Bosnic-Anticevich SZ. Lack of awareness of need to clean CFC-free metered-dose inhalers. J Asthma 2004;41(3): 367-373.
52. Marguet C, Couderc L, Le Roux P, Jeannot E, Lefay V, Mallet E. Inhalation treatment: errors in application and difficulties in accepers. tance of the devices are frequent in wheezy infants and young children. Pediatr Allergy Immunol 2001;12(4):224-230.
53. Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000;343(5):332-336.
54. Coutts JA, Gibson NA, Paton JY. Measuring compliance with inhaled medication in asthma. Arch Dis Child 1992;67(3):332-333.
55. Rand CS, Wise RA, Nides M, Simmons MS, Bleecker ER, Kusek JW, et al. Metered-dose inhaler adherence in a clinical trial. Am Rev Respir Dis 1992;146(6):1559-1564.
56. Cheng NG, Browne GJ, Lam LT, Yeoh R, Oomens M. Spacer compliance after discharge following a mild to moderate asthma attack. Arch Dis Child 2002;87(4):302-305.
57. Brennan VK, Osman LM, Graham H, Critchlow A, Everard ML. True device compliance: the need to consider both competence and contrivance. Respir Med 2005;99(1):97-102.
58. Everard ML. Role of inhaler competence and contrivance in "difficult asthma". Paediatr Respir Rev 2003;4(2):135-142.
59. Milgrom H, Bender B, Ackerson L, Bowry P, Smith B, Rand C. Noncompliance and treatment failure in children with asthma. J Allergy Clin Immunol 1996;98(6 Pt 1):1051-1077.
60. Laube BL. Treating diabetes with aerosolized insulin. Chest 2001; 120(3 Suppl):99S-106S.
61. Fink JB and Rubin BK. Problems with inhaler use: a call for improved clinician and patient education. Respir Care (2005, in press).